These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Design and Structural Evolution of Matrix Metalloproteinase Inhibitors. Fischer T; Senn N; Riedl R Chemistry; 2019 Jun; 25(34):7960-7980. PubMed ID: 30720221 [TBL] [Abstract][Full Text] [Related]
23. Matrix metalloproteinases: a therapeutic target in cardiovascular disease. Sierevogel MJ; Pasterkamp G; de Kleijn DP; Strauss BH Curr Pharm Des; 2003; 9(13):1033-40. PubMed ID: 12678855 [TBL] [Abstract][Full Text] [Related]
24. MMP-2 selectivity in hydroxamate-type inhibitors. Serra P; Bruczko M; Zapico JM; Puckowska A; Garcia MA; Martin-Santamaria S; Ramos A; de Pascual-Teresa B Curr Med Chem; 2012; 19(7):1036-64. PubMed ID: 22257051 [TBL] [Abstract][Full Text] [Related]
25. Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Overall CM; Kleifeld O Br J Cancer; 2006 Apr; 94(7):941-6. PubMed ID: 16538215 [TBL] [Abstract][Full Text] [Related]
26. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. Hurst DR; Schwartz MA; Jin Y; Ghaffari MA; Kozarekar P; Cao J; Sang QX Biochem J; 2005 Dec; 392(Pt 3):527-36. PubMed ID: 16026329 [TBL] [Abstract][Full Text] [Related]
27. Challenges with matrix metalloproteinase inhibition and future drug discovery avenues. Fischer T; Riedl R Expert Opin Drug Discov; 2021 Jan; 16(1):75-88. PubMed ID: 32921161 [TBL] [Abstract][Full Text] [Related]
28. Arylamino methylene bisphosphonate derivatives as bone seeking matrix metalloproteinase inhibitors. Tauro M; Laghezza A; Loiodice F; Agamennone M; Campestre C; Tortorella P Bioorg Med Chem; 2013 Nov; 21(21):6456-65. PubMed ID: 24071448 [TBL] [Abstract][Full Text] [Related]
29. Therapeutic implications of the specific inhibition of causative matrix metalloproteinases in experimental colitis induced by dextran sulphate sodium. Kobayashi K; Arimura Y; Goto A; Okahara S; Endo T; Shinomura Y; Imai K J Pathol; 2006 Jul; 209(3):376-83. PubMed ID: 16552705 [TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis. George SJ Expert Opin Investig Drugs; 2000 May; 9(5):993-1007. PubMed ID: 11060722 [TBL] [Abstract][Full Text] [Related]
31. Recent opportunities in matrix metalloproteinase inhibitor drug design for cancer. Zhong Y; Lu YT; Sun Y; Shi ZH; Li NG; Tang YP; Duan JA Expert Opin Drug Discov; 2018 Jan; 13(1):75-87. PubMed ID: 29088927 [TBL] [Abstract][Full Text] [Related]
32. Robust design of some selective matrix metalloproteinase-2 inhibitors over matrix metalloproteinase-9 through in silico/fragment-based lead identification and de novo lead modification: Syntheses and biological assays. Adhikari N; Halder AK; Mallick S; Saha A; Saha KD; Jha T Bioorg Med Chem; 2016 Sep; 24(18):4291-4309. PubMed ID: 27452283 [TBL] [Abstract][Full Text] [Related]
33. Sulphonamides: Deserving class as MMP inhibitors? Jain P; Saravanan C; Singh SK Eur J Med Chem; 2013 Feb; 60():89-100. PubMed ID: 23287054 [TBL] [Abstract][Full Text] [Related]
34. Matrix metalloproteinase inhibitors: a review on bioanalytical methods, pharmacokinetics and metabolism. Wang X; Li KF; Adams E; Van Schepdael A Curr Drug Metab; 2011 May; 12(4):395-410. PubMed ID: 21395524 [TBL] [Abstract][Full Text] [Related]
37. The design, structure, and therapeutic application of matrix metalloproteinase inhibitors. Skiles JW; Gonnella NC; Jeng AY Curr Med Chem; 2001 Mar; 8(4):425-74. PubMed ID: 11172697 [TBL] [Abstract][Full Text] [Related]
38. Matrix metalloproteinase inhibitors: a critical appraisal of design principles and proposed therapeutic utility. Dormán G; Cseh S; Hajdú I; Barna L; Kónya D; Kupai K; Kovács L; Ferdinandy P Drugs; 2010 May; 70(8):949-64. PubMed ID: 20481653 [TBL] [Abstract][Full Text] [Related]
39. Matrix Metalloproteinase Inhibitors as Investigational and Therapeutic Tools in Unrestrained Tissue Remodeling and Pathological Disorders. Liu J; Khalil RA Prog Mol Biol Transl Sci; 2017; 148():355-420. PubMed ID: 28662828 [TBL] [Abstract][Full Text] [Related]
40. The evolution of the matrix metalloproteinase inhibitor drug discovery program at abbott laboratories. Wada CK Curr Top Med Chem; 2004; 4(12):1255-67. PubMed ID: 15320725 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]